Ground-breaking CAR-T therapy approved in UK
Drug Discovery World
JANUARY 31, 2023
Axicabtagene ciloleucel (Yescarta, Kite) is a CAR-T therapy for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) who have had two or more lines of systemic therapy. Around 5,500 people are diagnosed with DLBCL each year in England.
Let's personalize your content